BS006 / Wuhan Binhui Biotech - LARVOL DELTA

Safety and preliminary efficacy of OH2 combined with BS006 sequential intratumoral injection in patients with advanced solid tumors: An open-label, dose-escalation phase Ib/II study. (ASCO 2026) - "Sequential intratumoral administration of OH2 and BS006 in heavily pre-treated patients is feasible and safe and results in reasonable DCR, with some patients achieving long-term clinical benefits. This study supports the clinical relevance of an HSV2-based platform combination of 2 oncolytic viruses encoding GM-CSF and T-cell redirected bispecific antibodies to warm up the cold TME. Further clinical research of the platform is warranted."

Clinical • Metastases • P1/2 data • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Colorectal Cancer • Leiomyosarcoma • Liver Cancer • Melanoma • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CSF2

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd.

New P1/2 trial • Biliary Tract Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Melanoma • Solid Tumor

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection (clinicaltrials.gov) - P1 | N=29 | Suspended | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2026 ➔ Dec 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jun 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Trial suspension • Breast Cancer • Melanoma • Solid Tumor

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2023 ➔ Dec 2023

Enrollment open • Metastases • Oncolytic virus • Trial initiation date • Breast Cancer • Melanoma • Oncology • Solid Tumor

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection (clinicaltrials.gov) - P1 | N=29 | Not yet recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncolytic virus • Breast Cancer • Melanoma • Oncology • Solid Tumor

CC-OV01: First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Zhongnan Hospital

New P1 trial • Cervical Cancer • Herpes Simplex • Oncology • Solid Tumor • Uterine Cancer